Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:3713 |
| Name | ovary adenocarcinoma |
| Definition | An ovarian carcinoma that derives_from epithelial cells of glandular origin. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:7816 |
| Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma ovary adenocarcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| NRAS Q61K | ASTX029 | ovary adenocarcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02068794 | Phase Ib/II | MV-NIS | MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Unknown status | USA | ITA | GBR | ESP | 2 |
| NCT02834013 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
| NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
| NCT04498117 | Phase III | Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5) | Active, not recruiting | USA | ITA | HUN | ESP | CZE | CAN | BRA | BEL | ARG | 5 |
| NCT05479045 | Phase II | Nivolumab + NY-ESO-1 peptide vaccine | A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | Not yet recruiting | USA | 0 |